ClinicalTrials.Veeva

Menu
N

Neurobehavioral Research | Cedarhurst, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Iclepertin
BHV-7000
SEP-363856
BI 1569912
BI 1358894

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 7 total trials

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accept...

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: SEP-363856

This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did...

Enrolling
Depressive Disorder, Major
Drug: BI 1569912
Drug: Placebo

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Active, not recruiting
Schizophrenia
Drug: Placebo
Drug: Iclepertin

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

Trial sponsors

Boehringer Ingelheim logo
Biohaven logo
Otsuka logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems